Moringa oleifera leaf
Phase 1Small molecule
Moringa oleifera leaf is one of 25 small molecule programs targeting Otomycosis. It is currently in Phase 1.
2
Indications
5
Total Trials
2
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in Gingivitis
#DrugCompanyPhaseTrials
1Flagyl
DDePuy Orthopaedics
Approved
Peridex
DDexcel Pharma Technologies Ltd.
Approved
Cetylpyridinium Chloride
SanofiApproved
Tea Tree Oil
FFederal University of São Paulo
Approved
Triclosan
CColgate Palmolive
Phase 3
Active Comparator
ModernaPhase 2
Negative Control
GSKPhase 3
Test
RRespirent Pharmaceuticals Co Ltd.
Phase 2
Sodium Laural Sulfate
GSKPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nonvital Primary Molars2 trials
Moringa Oleifera vs Sodium Hypochlorite for Root Canal Irrigation in Nonvital Primary Molars
Not yet recruiting·—·N/A·NCT06971055·38 enrolled
Evaluation of Moringa Oleifera Leaf Extract Versus Sodium Hypochlorite in Pulpectomy of Nonvital Primary Molars
Not yet recruiting·—·N/A·NCT06948526·50 enrolled
Gingivitis1 trial
Anti-Plaque and Anti-Gingivitis Effects of Moringa Plant Extract and Fluoride Toothpastes
Unknown status·—·N/A·NCT05390099·60 enrolled
Otomycosis1 trial
Antifungal Potential of Moringa Olifera Against Otomycosis
Completed·—·Phase 1·NCT04768829·10 enrolled
Moringa Oleifera1 trial
Effect of Moringa Oleifera Capsule in Increasing Breast Milk Volume in Early Postpartum Patients
Completed·—·Phase 4·NCT04487613·88 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Moringa oleifera leaf. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCairo University